Patent · US Active

Anti-SIRPa antibodies and their therapeutic applications

US12252546B2 · kind B2 · utility

0Cited by
0References
23Claims
0Family size

Assignee

Inventors

Key dates

Filing dateFeb 25, 2022
Grant dateMar 18, 2025
Priority date
Expiry dateFeb 25, 2042

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2333/70596
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention provides new anti-SIRPa antibodies able to specifically antagonize the interaction between SIRPa and CD47, without affecting the interaction between SIRPg and CD47, and their uses.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.